Pacific Biosciences of California, Inc. PACB

Company Overview

Pacific Biosciences of California, Inc. (“PacBio”) is a U.S.-based biotechnology company focused on developing and commercializing advanced genomic sequencing technologies for life sciences research and clinical applications. The company operates primarily within the genomics, molecular diagnostics, and biotechnology tools industries. PacBio is best known for its long-read DNA sequencing platforms built on Single Molecule, Real-Time (SMRT) sequencing technology, which is designed to deliver highly accurate genomic data for applications including whole genome sequencing, transcriptomics, epigenetics, oncology research, agricultural genomics, and infectious disease analysis.

The company’s primary revenue drivers include sales of sequencing instruments, consumables, and related services. Key product lines include the Revio System, Sequel IIe System, and associated consumable kits and software platforms. PacBio serves academic institutions, government laboratories, pharmaceutical companies, biotechnology firms, and clinical research organizations globally. The company was founded in 2004 and is headquartered in Menlo Park, California. Over time, PacBio evolved from an emerging sequencing technology developer into a commercial genomics platform provider competing in the high-accuracy long-read sequencing market. Its strategic positioning has been associated with high-fidelity (“HiFi”) sequencing accuracy and the ability to resolve structurally complex regions of the genome that can be difficult for short-read sequencing technologies to analyze effectively.